Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Teva Pharmaceutical Industries's annualizedNet Income for the quarter that ended in Dec. 2023 was $1,716 Mil. Teva Pharmaceutical Industries's average total tangible assets for the quarter that ended in Dec. 2023 was $20,297 Mil. Therefore, Teva Pharmaceutical Industries's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was 8.45%.
The historical rank and industry rank for Teva Pharmaceutical Industries's Return-on-Tangible-Asset or its related term are showing as below:
TEVA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -62.89 Med: -3.68 Max: 13.71
Current: -2.78
During the past 13 years, Teva Pharmaceutical Industries's highest Return-on-Tangible-Asset was 13.71%. The lowest was -62.89%. And the median was -3.68%.
TEVA's Return-on-Tangible-Asset is ranked worse than 61.83% of 1082
companies
in the Drug Manufacturers industry
Industry Median: 1.955
vs TEVA: -2.78
Teva Pharmaceutical Industries Return-on-Tangible-Asset Historical Data
The historical data trend for Teva Pharmaceutical Industries's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries Return-on-Tangible-Asset Distribution
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2023) net income data.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Teva Pharmaceutical Industries Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TEVA has been successfully added to your 